Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open-Label, Phase IV Trial

Helicobacter

Volumn 17, Issue 6, 2012, Pages 458-465

  Liang, Jie ^a   Li, Jun ^a   Han, Ying ^a   Xia, Jielai ^a   Yang, Yunsheng ^a   Li, Wen ^b   Zhang, Shutian ^b   Wu, Yongdong ^c   Yuan, Yaozong ^c   Li, Zhaoshen ^d   Du, Yiqi ^e   Chen, Minhu ^e   Chen, Baili ^f   Jiang, Bo ^g   Bai, Yang ^g   Wen, Qinsheng ^a   Wu, Kaichun ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^g SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Bismuth containing quadruple therapy; Ecabet sodium containing quadruple therapy; Helicobacter pylori eradication

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; ECABET; OMEPRAZOLE;

ADULT; AGED; ARTICLE; BACKACHE; BEDTIME DOSAGE; CENTRAL NERVOUS SYSTEM DISEASE; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FACIAL SWELLING; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION; INFESTATION; KIDNEY FUNCTION; LEUKOCYTE; LIVER FUNCTION; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MELANOGLOSSIA; MORNING DOSAGE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; ORAL BLISTER; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PIGMENT DISORDER; PRIORITY JOURNAL; QUADRUPLE THERAPY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SOMNOLENCE; SWELLING; TASTE DISORDER; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; UREA BREATH TEST; URINALYSIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BREATH TESTS; CHINA; CITIES; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; UREA; YOUNG ADULT;

EID: 84867703856     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2012.00971.x     Document Type: Article

References (43)

1. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F; Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377:905-13.
2. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009;374:1449-61.
3. Zhang WD, Hu FL, Xiao SD, Xu ZM. Prevalence of Helicobacter pylori infection in China. Modern digestion and intervention. 2010;15:265-70.
4. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
5. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597-604.
6. Megraud F. Helicobacter pylori and antibiotic resistance. Gut 2007;56:1502.
7. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25.
8. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
9. van der Wouden EJ, Thijs JC, van Zwet AA, et al. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti- Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999;94:1751-9.
10. Vakil N. Helicobacter pylori treatment: is sequential or quadruple therapy the answer? Rev Gastroenterol Disord 2008;8:77-82.
11. Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003;98:562-7.
12. Gorbach SL. Bismuth therapy in gastrointestinal diseases. Gastroenterology 1990;99:863-75.
13. Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008;14:7361-70.
14. Xia HH, Yu Wong BC, Talley NJ, Lam SK. Alternative and rescue treatment regimens for Helicobacter pylori eradication. Expert Opin Pharmacother 2002;3:1301-11.
15. Yang Kim H, Hahm KB, Choi MG, Rew JS, Seol SY, Chun HJ, Lee OY, Hong WS. Prospective multi-center trial for the efficacy of ecabet sodium on the relief of dyspepsia in Korean patients with chronic gastritis. J Clin Biochem Nutr 2007;41:160-8.
16. Hayashi S, Sugiyama T, Yachi A, Yokota K, Hirai Y, Oguma K, Fujii N. Effect of ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells. J Gastroenterol 1997;32:593-7.
17. Shimoyama T, Fukuda S, Liu Q, Nakaji S, Munakata A, Sugawara K. Ecabet sodium inhibits the ability of Helicobacter pylori to induce neutrophil production of reactive oxygen species and interleukin-8. J Gastroenterol 2001;36:153-7.
18. Kagaya H, Kato M, Komatsu Y, Mizushima T, Sukegawa M, Nishikawa K, Hokari K, Takeda H, Sugiyama T, Asaka M. High-dose ecabet sodium improves the eradication rate of Helicobacter pylori in dual therapy with lansoprazole and amoxicillin. Aliment Pharmacol Ther 2000;14:1523-7.
19. Asakuma Y, Kudo M, Matsui S, Okada M, Kawasaki M, Umehara Y, Ichikawa T, Kitai S. Possible Mechanism Comparison of an ecabet sodium and proton pump inhibitor (PPI) combination therapy with PPI alone in the treatment of endoscopic submucosal dissection (ESD)-induced ulcers in early gastric cancer: prospective randomized study. Hepatogastroenterology 2009;95:1270-3.
20. Kim HW, Kim GH, Cheong JY, Yang US, Park SK, Song CS, Kang DH, Song GA. H. pylori eradication: a randomized prospective study of triple therapy with or without ecabet sodium. World J Gastroenterol 2008;14:908-12.
21. Koizumi W, Tanabe S, Nakatani K, Ishido K, Nishimura K, Azuma M, Ae T, Sasaki T, Higuchi K, Katada C. Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study). J Clin Pharm Ther 2010;35:303-7.
22. Zhang WD, Xiao SD, Hu FL, Hu PJ, Xu ZM. Consensus on certain problems of Helicobacter pylori. World Chinese Journal of Digestology 2000;8:219-20.
23. Lee BH, Kim N. Quadruple or triple therapy to eradicate H. pylori. Lancet 2011;377:877-8.
24. Lee JH, Kim JJ, Hahm KB, et al.Efficacy and safety of ecabet sodium on functional dyspepsia: a prospective, double-blinded, randomized, multi-center controlled trial. World J Gastroenterol 2006;12:2756-61.
25. Hu FL. Helicobacter pylori infection treatment status and challenges. Natl Med J China 2010;2:73-4.
26. Cai W, Zhou L, Ren W, Deng L, Yu M. Variables influencing outcome of Helicobacter pylori eradication therapy in South China. Helicobacter 2009;14:91-6.
27. Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010;15:233-8.
28. Gao W, Cheng H, Hu F, Li J, Wang L, Yang G, Xu L, Zheng X. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 2010;15:460-6.
29. Yao CL, Zhu JW, Li JP. Analysis on Helicobacter pylori antibiotic resistance in Xi'an in 2005. J Pract Med Tech 2006;13:3590-1.
30. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K; Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010;15:1-20.
31. Fock KM, Katelaris P, Sugano K, et al.Second Asia-Pacific Conference.Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-600.
32. O'Connor A, Gisbert JP, McNamara D, O'Morain C. Treatment of Helicobacter pylori Infection 2011. Helicobacter 2011;16(Suppl. 1):53-8.
33. Gisbert JP. A new single-capsule, bismuth-containing quadruple therapy. Nat Rev Gastroenterol Hepatol 2011;8:307-9.
34. Liou JM, Lin JT, Chang CY, Chen MJ, Cheng TY, Lee YC, Chen CC, Sheng WH, Wang HP, Wu MS. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut 2010;59:572-8.
35. Lee BH, Kim N, Hwang TJ, Lee SH, Park YS, Hwang JH, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010;15:38-45.
36. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010;105:65-73.
37. Buge A, Rancurel G, Poisson M, Gazengel J, Dechy H, Fressinaud L, Emile J. 20 cases of acute encephalopathy with myoclonia during treatment with oral bismuth salts. Ann Med Intern 1974;124:877-88.
38. Slikkerveer A, de Wolff FA. Pharmacokinetics and toxicity of bismuth compounds. Med Toxicol Adverse Drug Exp 1989;4:303-23.
39. Bader JP. The safety profile of De-Nol. Digestion 1987;37(Suppl. 2):53-9.
40. Furuta T, Kato M, Sugimoto M, et al.; Japan Gast Study Group. Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection. Intern Med 2011;50:369-74.
41. Costa F, D'Elios MM. Management of Helicobacter pylori infection. Expert Rev Anti Infect Ther 2010;8:887-92.
42. Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter 2008;13:532-41.
43. Kuo CH, Wang SS, Hsu WH, et al.Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter 2010;15:265-72.